Granules India’s wholly owned foreign subsidiary -- Granules Pharmaceuticals, Inc., has received tentative approval from US Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) for Colchicine Capsules, 0.6 mg. It is bioequivalent to the reference listed drug product (RLD), Mitigare Capsules, 0.6 mg, of Hikma International Pharmaceuticals LLC.
The company now has a total of 22 ANDA approvals from USFDA (21 Final approvals and 1 tentative approval). Colchicine capsules are indicated for prophylaxis of gout flares in adults. The Mitigare brand and generic had U.S. sales of approximately $84 million MAT for the most recent twelve months ending in December 2019. Mitigare is a registered trademark of Hikma Pharmaceuticals USA Inc.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.60 |
| Dr. Reddys Lab | 1232.65 |
| Cipla | 1242.10 |
| Zydus Lifesciences | 944.25 |
| Lupin | 2328.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: